Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Drug Evaluation × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2 Genitourinary 1 Breast 1

Conditions

Upper Tract Urothelial Carcinomas 1

Interventions

Docetaxel 60 pembrolizumab 39 Prednisone 38 Nivolumab 35 enzalutamide 30 Sunitinib 30 Gemcitabine 30 Cyclophosphamide 27 Sorafenib 22 Radiotherapy 22 Magnetic Resonance Spectroscopy 22 Leuprolide 22 Everolimus 21 Abiraterone Acetate 21 Cisplatin 18 bicalutamide 17 avelumab 16 Interleukin-2 15 Goserelin 15 Carboplatin 15 fludarabine 14 atezolizumab 14 Radiosurgery 14 Bevacizumab 14 abiraterone 13 Radiotherapy, Intensity-Modulated 13 durvalumab 12 cabozantinib 12 Doxorubicin 12 cabazitaxel 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04197986 2024-03-13

PROOF302

QED Therapeutics, a BridgeBio company

Phase 3 Terminated

39 enrolled 31 charts

Upper Tract Urothelial Carcinomas

Data powered by HemOnc (CC BY 4.0) Colophon ⚡